NCT00262730 - Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

August 31, 2009

Study Completion Date

April 30, 2010

Conditions

Glioblastoma Multiforme

Interventions

DRUG

poly ICLC

20 mcg/kg 3x each week (Maintenance cycles)

DRUG

temozolomide

daily 75mg/m2 6wks concomitant therapy Wk 1 - days 1-5 150-200 mg/m2 maintenance cycles (adjuvant)

RADIATION

radiation therapy

RT: 60 Gy (6 weeks) concomitant therapy

Trial Locations (9)

Winship Cancer Institute of Emory University, Atlanta

Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham, Birmingham

Cleveland Clinic Taussig Cancer Center, Cleveland

Josephine Ford Cancer Center at Henry Ford Hospital, Detroit

H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

Massachusetts General Hospital Cancer Center, Boston

Wake Forest University Comprehensive Cancer Center, Winston-Salem

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER